Brief: Alpha Tau Announces Alpha DaRT Treatment Of First 2 Patients In Multicenter Recurrent Skin Cancer Trial
08/03/2023 22:03
March 8 (Reuters) - Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES ALPHA DART™ TREATMENT OF FIRST TWO
PATIENTS
IN ITS PIVOTAL MULTICENTER RECURRENT SKIN CANCER (RESTART) TRIAL
Source text for Eikon: ID:nGNX1Dg0nh
Further company coverage: DRTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer